Back to the Top
Identification and Validation of Biomarkers
Dear All:
I am moderating a round table discussion on "Identification and
Validation of Biomarkers" on November 19, 2008 Wednesday 9.00 am
-11.00 am during the upcoming AAPS annual meeting Biomarkers
identification for a specific disease and proper validation of their
quantitative methodology plays a role in setting up biomarker program.
We evaluate various strategies for a robust biomarkers program. I am
requesting you to post any questions you may have so that we can try
to get answers for your question during this round table and I will
post discussion results in these fora.
Please send your questions to prasad.tata.aaa.covidien.com
Thanks,.
Prasad
Prasad NV Tata, MS, Ph.D., FCP
Manager-Pharmacokinetics
Mallinckrodt, Inc.
675 McDonnell Blvd.
Saint Louis, MO 63134
e-mail: prasad.tata.-a-.covidien.com
--
Development and Maintaining a Biomarker Monitoring Program - Round
table discussion during AAPS annual meeting.
Dear All:
I am moderating a round table discussion on "Development and
Maintaining a Biomarker Monitoring Program" on November 19, 2008
Wednesday 1.00 am -3..00 pm during the upcoming AAPS annual meeting
in Atlanta during this round table we discuss Biomarkers have
attained a pivotal place in drug development. There needs to be a
clear understanding of rational biomarker identification and validated
programs in place for meaningful drug development process. Properly
selected biomarkers offer efficient drug development process. In this
session we discuss how to run a meaningful biomarker program. I am
requesting you to post any questions you may have so that we can try
to get answers for your question during this round table and I will
post discussion results in these fora.
Please send your questions to prasad.tata.at.covidien.com
Thanks,.
Prasad
Prasad NV Tata, MS, Ph.D., FCP
Manager-Pharmacokinetics
Mallinckrodt, Inc.
675 McDonnell Blvd.
Saint Louis, MO 63134
e-mail: prasad.tata.aaa.covidien.com
Back to the Top
The following message was posted to: PharmPK
Dear Prasad
I think it would be very interesting to hear a compare and
contrast discussion regarding how identification and validation
efforts differ for drug development paths where the drug candidate is
not yet approved (ie: developing for the first indication) versus an
approved drug going for additional indications.
Regards,
Michael
--
Michael D. Karol, Ph.D.
Senior Director, Clinical Pharmacology
Synta Pharmaceuticals Corp.
45 Hartwell Ave
Lexington, MA 02421
MKarol.-at-.SyntaPharma.Com
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Biomarker roundtables at AAPS in Atlanta" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)